StockNews.com Begins Coverage on VBI Vaccines (NASDAQ:VBIV)

StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research note released on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Trading Down 4.2 %

Shares of VBI Vaccines stock opened at $0.57 on Friday. The firm’s 50-day simple moving average is $0.61 and its 200-day simple moving average is $0.61. VBI Vaccines has a twelve month low of $0.45 and a twelve month high of $3.47.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.